Archive for the ‘Crispr’ Category

GlobalCRISPR and CAS Gene MarketResearch Report is a resource, which provides current as well as upcoming technical and financial details of the industry to 2027. This report gives you so important and essentials data of Market size, share, trends, Growth, applications, forecast and cost analysis. Delivery development in North America, China, Europe, and South East Asia, Japan as well as in the Globe. The report proves to be indispensable when it comes to market definition, classifications, applications and engagements.

The market report also computes the market size and revenue generated from the sales. The industry analysis report presents the key statistics on the market status of global and regional manufacturers and also acts as a valuable source of leadership and direction. What is more, the CRISPR and CAS Gene market report analyses and provides historic data along with the current performance of the market.

Get a Free Sample Copy of the CRISPR and CAS Gene Market Report with Latest Industry Trends @https://www.coherentmarketinsights.com/insight/request-sample/2598

Global CRISPR and CAS Gene Market competition by Top Key Players: Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc.

CRISPR and CAS Gene Market section by Region:

Segmentation: The report has been separated into different categories, such as product type, application, end user, and region. Every segment is evaluated based on the CAGR, share and growth potential. In the regional analysis, the report highlights the prospective region, which should generate opportunities in the global CRISPR and CAS Gene market in the years to come. This segmented analysis will surely prove to be a useful tool for readers, stakeholders and market participants to get a full picture of the CRISPR and CAS Gene global market and its growth potential in the years to come.

The CRISPR and CAS Gene Market report offers a plethora of insights which include:

Changing consumption patterns among individuals globally.

Historical and future progress of the global CRISPR and CAS Gene market.

Region-wise and country-wise segmentation of the CRISPR and CAS Gene market to understand the revenue, and growth lookout in these areas.

Accurate Year-on-Year growth of the global CRISPR and CAS Gene market.

Important trends, including proprietary technologies, ecological conservation, and globalization affecting the global CRISPR and CAS Gene market.

Need a discount?

Note: *The discount is offered on the Standard Price of the report.

To get Incredible Discounts on this Premium Report, Click Here @https://www.coherentmarketinsights.com/insight/request-discount/2598

Important Information that can be extracted from the Report:

Assessment of the COVID-19 impact on the growth of the CRISPR and CAS Gene Market

Successful market entry strategies formulated by emerging market players

Pricing and marketing strategies adopted by established market players

Country-wise assessment of the CRISPR and CAS Gene Market in key regions

Year-on-Year growth of each market segment over the forecast period 2026

The CRISPR and CAS Gene Market report considers the following years to predict market growth:

Historic Year: 2014 2018

Base Year: 2019

Estimated Year: 2020

Forecast Year: 2020 2027

The Global CRISPR and CAS Gene Market is displayed in 13 Chapters:

Chapter 1: Market Overview, Drivers, Restraints and Opportunities

Chapter 2: Market Competition by Manufacturers

Chapter 3: Production by Regions

Chapter 4: Consumption by Regions

Chapter 5: Production, By Types, Revenue and Market share by Types

Chapter 6: Consumption, By Applications, Market share (%) and Growth Rate by Applications

Chapter 7: Complete profiling and analysis of Manufacturers

Chapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Market Effect Factors Analysis

Chapter 12: Market Forecast

Chapter 13: CRISPR and CAS Gene Research Findings and Conclusion, Appendix, methodology and data source

Have Any Query? Ask Our Expert @ https://www.coherentmarketinsights.com/insight/request-customization/2598

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia or Oceania [Australia and New Zealand].

Contacts Us:

Mr. ShahCoherent Market Insights,1001 4th Ave,#3200 Seattle, WA 98154, U.S.Email:[emailprotected]Phone: US +1-206-701-6702/UK +44-020 8133 4027

Continue reading here:
CRISPR and CAS Gene Market Growth Analysis with Top Players Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio...

Final Report will add the analysis of the impact of COVID-19 on this industry.

Global Crispr And Crispr-Associated (Cas) Genes Market Research Report 2020-2025 is a historical overview and in-depth study on the current & future market of the Crispr And Crispr-Associated (Cas) Genes industry. The report represents a basic overview of the Crispr And Crispr-Associated (Cas) Genes market share, competitor segment with a basic introduction of key vendors, top regions, product types, and end industries. This report gives a historical overview of the Crispr And Crispr-Associated (Cas) Genes market trends, growth, revenue, capacity, cost structure, and key drivers analysis.

Get a Sample PDF of report @ https://www.industryresearch.biz/enquiry/request-sample/16203415

In Chapter 2.4 of the report, we share our perspectives for the impact of COVID-19 from the long and short term.In chapter 3.4, we provide the influence of the crisis on the industry chain, especially for marketing channels.In chapters 8-13, we update the timely industry economic revitalization plan of the country-wise government.

The report mainly studies the Crispr And Crispr-Associated (Cas) Genes market size, recent trends and development status, as well as investment opportunities, market dynamics (such as driving factors, restraining factors), and industry news (like mergers, acquisitions, and investments). Technological innovation and advancement will further optimize the performance of the product, making it more widely used in downstream applications. Moreover, Porters Five Forces Analysis (potential entrants, suppliers, substitutes, buyers, industry competitors) provides crucial information for knowing the Crispr And Crispr-Associated (Cas) Genes market.

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT

Key players in the global Crispr And Crispr-Associated (Cas) Genes market covered in Chapter 5:

Global Crispr And Crispr-Associated (Cas) Genes Industry 2020 Market Research Report also provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Top Countries Data Covered in Crispr And Crispr-Associated (Cas) Genes Market Report are United States, Canada, Mexico, Germany, UK, France, Italy, Spain, Russia, China, Japan, South Korea, Australia, India, Southeast Asia, Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Brazil, Argentina, Columbia, Chile, and Others

Scope of the Crispr And Crispr-Associated (Cas) Genes Market Report:

Enquire before purchasing this report https://www.industryresearch.biz/enquiry/pre-order-enquiry/16203415

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 8-13:

In Chapter 6, on the basis of types, the Crispr And Crispr-Associated (Cas) Genes market from 2015 to 2025 is primarily split into:

In Chapter 7, on the basis of applications, the Crispr And Crispr-Associated (Cas) Genes market from 2015 to 2025 covers:

Get a sample copy of the Crispr And Crispr-Associated (Cas) Genes Market Report 2020

Global Crispr And Crispr-Associated (Cas) Genes Market providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis are also carried out. The Global Crispr And Crispr-Associated (Cas) Genes market development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.

Some of the key questions answered in this report:

With tables and figures helping analyze worldwide Global Crispr And Crispr-Associated (Cas) Genes market growth factors, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Purchase this report (Price 3500 USD for a single-user license) https://www.industryresearch.biz/purchase/16203415

Years considered for this report:

Key Points from TOC:

1 Market Overview1.1 Product Definition and Market Characteristics1.2 Global Crispr And Crispr-Associated (Cas) Genes Market Size1.3 Market Segmentation1.4 Global Macroeconomic Analysis1.5 SWOT Analysis

2. Market Dynamics2.1 Market Drivers2.2 Market Constraints and Challenges2.3 Emerging Market Trends2.4 Impact of COVID-192.4.1 Short-term Impact2.4.2 Long-term Impact

3 Associated Industry Assessment3.1 Supply Chain Analysis3.2 Industry Active Participants3.2.1 Suppliers of Raw Materials3.2.2 Key Distributors/Retailers3.3 Alternative Analysis3.4 The Impact of Covid-19 From the Perspective of Industry Chain

4 Market Competitive Landscape4.1 Industry Leading Players4.2 Industry News4.2.1 Key Product Launch News4.2.2 M&A and Expansion Plans

5 Analysis of Leading Companies5.1 Company 15.1.1 Company 1 Company Profile5.1.2 Company 1 Business Overview5.1.3 Company 1 Crispr And Crispr-Associated (Cas) Genes Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)5.1.4 Company 1 Crispr And Crispr-Associated (Cas) Genes Products Introduction

5.2 Company 25.2.1 Company 2 Company Profile5.2.2 Company 2 Business Overview5.2.3 Company 2 Crispr And Crispr-Associated (Cas) Genes Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)5.2.4 Company 2 Crispr And Crispr-Associated (Cas) Genes Products Introduction

5.3 Company 35.3.1 Company 3 Company Profile5.3.2 Company 3 Business Overview5.3.3 Company 3 Crispr And Crispr-Associated (Cas) Genes Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)5.3.4 Company 3 Crispr And Crispr-Associated (Cas) Genes Products Introduction

5.4 Company 45.4.1 Company 4 Company Profile5.4.2 Company 4 Business Overview5.4.3 Company 4 Crispr And Crispr-Associated (Cas) Genes Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)5.4.4 Company 4 Crispr And Crispr-Associated (Cas) Genes Products Introduction

6 Market Analysis and Forecast, By Product Types6.1 Global Crispr And Crispr-Associated (Cas) Genes Sales, Revenue and Market Share by Types (2015-2020)6.2 Global Crispr And Crispr-Associated (Cas) Genes Market Forecast by Types (2020-2025)6.3 Global Crispr And Crispr-Associated (Cas) Genes Sales, Price and Growth Rate by Types (2015-2020)6.4 Global Crispr And Crispr-Associated (Cas) Genes Market Revenue and Sales Forecast, by Types (2020-2025)

7 Market Analysis and Forecast, By Applications7.1 Global Crispr And Crispr-Associated (Cas) Genes Sales, Revenue and Market Share by Applications (2015-2020)7.2 Global Crispr And Crispr-Associated (Cas) Genes Market Forecast by Applications (2020-2025)7.3 Global Revenue, Sales and Growth Rate by Applications (2015-2020)7.4 Global Crispr And Crispr-Associated (Cas) Genes Market Revenue and Sales Forecast, by Applications (2020-2025)

8 Market Analysis and Forecast, By Regions8.1 Global Crispr And Crispr-Associated (Cas) Genes Sales by Regions (2015-2020)8.2 Global Crispr And Crispr-Associated (Cas) Genes Market Revenue by Regions (2015-2020)8.3 Global Crispr And Crispr-Associated (Cas) Genes Market Forecast by Regions (2020-2025)Continued.

Detailed TOC of Global Crispr And Crispr-Associated (Cas) Genes Market @ https://www.industryresearch.biz/TOC/16203415

About Us:

Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided todays businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors. Industry Research is the credible source for gaining the market reports that will provide you with the lead your business needs.

Contact Info:

Name: Mr. Ajay More

E-mail: [emailprotected]

Organization: Industry Research Biz

Phone: US +1424 253 0807 / UK +44 203 239 8187

Our Other Reports:

Global Automatic Dispenser Market Size Share, 2020 Movements by Development Analysis, Progression Status, Prominent Players Updates, Revenue Expectation till 2026 Research Report by Industry Research Biz

Gas Engine Karts Market Size 2020 Growing Rapidly with Modern Trends, Development Status, Investment Opportunities, Share, Revenue, Demand and Forecast to 2026 Says Industry Research Biz

Parcel Sorting System Market Size, Share 2020 By Development History, Business Prospect, Trend, Key Manufacturers, Price, Supply Demand, Growth Factor and End User Analysis, Outlook till 2025

Global Resistant Maltodextrin Market Size & Share, 2020 Movements by Latest Trend Analysis, Progression Status, Revenue Expectation to 2026, Research Report by Industry Research Biz

Post-Tensioning System Market Size 2020 Analysis By Business Share, Strategies, Opportunities, Revenue Expectation, Future Trends, Prominent Players, Covid-19 Impact Analysis and Forecast till 2025

Global Intracranial Pressure (ICP) Monitoring Devices Market Size 2020 Growing Rapidly with Recent Developments, Industry Share, Trends, Demand, Revenue, Key Findings, Latest Technology, Industry Expansion Strategies till 2024

Mobile Photo Printer Market Size 2020 By Global Business Trends, Share, Future Demand, Progress Insight, Modest Analysis, Statistics, Regional Growth, and Forecast to 2025

More:
Crispr And Crispr-Associated (Cas) Genes Market Size 2020 Explosive Factors of Revenue By Industry Statistics, Progression Status, Emerging Demands,...

The Global CRISPR Market research report presentation is a decisive gateway into unfurling various significant events and developments prevalent in the market spectrum that collectively usher into a flourishing growth outlook in the global CRISPR market. Optimum research hint that the aforementioned market is likely to register a robust growth, reaching over xx million USD through the forecast span, 2020-26, maintaining a steady CAGR valuation of xx% throughout.

Request a sample of CRISPR Market report @ https://www.orbismarketreports.com/sample-request/122674

According to meticulous primary and secondary research endeavors on the part of our in-house research experts, the global CRISPR market is likely to emerge from the catastrophic after-effects of the unprecedented COVID-19 pandemic that has severely crippled businesses and paralyzed industries globally. However, post dedicated research initiatives, research suggests an optimistic comeback, suggesting healthy growth at the end of 2026.

Key Manufacturers Analysis:

Intellia Therapeutics, Inc.Transposagen Biopharmaceuticals, Inc.GenScript Biotech CorporationThermo Fisher Scientific, Inc.GE Healthcare Dharmacon IncIntegrated DNA Technologies, Inc.CRISPR TherapeuticsAddgene

The report segregates the market into various segments such as type and application that continue to remain prominent growth influencers in global CRISPR market. To evoke resilient market specific growth factors that constantly shape growth prospects in global CRISPR market, this ardent research report sheds light on market segmentation based on which this research presentation aims to equip report readers with versatile understanding about potential market segments that encourage sustainable revenue generation despite stringent competition.

CRISPR Market Analysis by Types:

Design ToolsPlasmid and VectorCas9 and g-RNADelivery System Products

CRISPR Market Analysis by Applications:

Genome EditingGenetic EngineeringGMO and CropsHuman Stem CellsOthers

Make an enquiry of this report @ https://www.orbismarketreports.com/enquiry-before-buying/122674

Global CRISPR Market: Regional Review

1. The report is designed to adequately highlight a detailed matrix of region-wise and country-specific classification, depicting volume specific production details as well as refers to consumption patterns, further proceeding with minute details related to revenue generation and growth progress throughout the growth tenure, 2020-26.2. Additionally, in the report on global CRISPR market, research initiatives have suggested significant developments encompassing significant developments across diverse regions as well as countries that enable successful growth prognosis through the forecast span, 2020-26.3. The report draws specific references of country-specific developments across both emerging and developed economies alike that collectively contribute towards uncompromised and healthy growth trail in the global CRISPR market throughout the forecast span.4. The CRISPR market report is systematically classified into graphs, charts and statistical presentation to mimic steady growth.

Report Investment Guide:

1. This meticulous research documentation endeavors to offer extensive overview of the industry and studies the CRISPR market at a multi-faceted perspective.2. The report in order to uphold real time market status is hovering mainly across important areas such as real time market growth status to encourage accurate market specific decisions.3. The CRISPR report is focusing specifically across a range of key development areas such as dynamic segmentation, cross sectional analysis of the target market.4. This elaborate report also is a ready-to-go market specific document encompassing regional overview, opportunity mapping, and competition analysis.

Place a direct purchase order @ https://www.orbismarketreports.com/buy-now/122674

ABOUT US:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

CONTACT US:

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: +1 (972)-362-8199; +91 895 659 5155

Read more here:
Global CRISPR Market 2020 Size, Growth Drivers, SWOT Analysis, 2026 Key Companies Overview- Intellia Therapeutics, Inc., Transposagen...

A2Z Market Research announces the release of the Gene Editing Tools Market research report. The market is predicted to grow at a healthy pace in the coming years. Gene Editing Tools Market 2020 research report presents an analysis of market size, share, and growth, trends, cost structure, statistical and comprehensive data of the global market. The Market report offers remarkable data regarding the industrys growth parameters, the current state of the market in terms of analysis of possible economic situations, and macroeconomic analysis.

Gene Editing is a type of genetic engineering in which DNA is inserted, deleted, modified, or replaced in the genome of a living organism. .This process requires specialized tools to be carried out and is generally undertaken in different labs with the help of engineered nucleases. The global gene-editing tool market is expected to register significant growth in the near future attributed to the rise in the prevalence of cancer and genetic disorders such as sickle cell diseases, Alzheimers disease, and others, for which there are close to none or very limited therapy options available, along with other genetic and metabolic disorders such as diabetes, obesity, and others. Gene Editing Tools Market is growing at a CAGR of +18% during the forecast period 2020-2026.

Sample Report with Latest Industry Trends @:

https://www.a2zmarketresearch.com/sample?reportId=313215

The top companies in this report include:

Thermofisher Scientific, CRISPR Therapeutics, Editas Medicine, NHGRI, Intellia Therapeutics, Merck KGaA, and others.

This report provides an in-depth review of the current state of the Gene Editing Tools market, daring its growth and all other essential elements in all of the major markets of the county.It presents a gigantic amount of market data, compiled using myriad primary and secondary research practices.The data in this report has been reduced on a business basis using various systematic methods.

For a comprehensive analysis, the Gene Editing Tools market is segmented by product type, region, and application. Due to its regional focus, the market is alien to North America, Europe, Asia-Pacific, the Middle East, and Africa as well as Latin America. Major companies are working on distributing their products and services across different regions. In addition, procurements and associations from some of the leading organizations. All of the factors intended to drive the global marketplace are examined in depth.

Get Impressive [emailprotected]:

https://www.a2zmarketresearch.com/discount?reportId=313215

This report gives an in-depth and broad understanding of the Gene Editing Tools Market. With exact data cover all key features of the current market, this report offers widespread data from leading companies. Appreciative of the market state by amenability of correct historical data regarding each and every sector for the forecast period is mentioned. Driving forces, restraints, and opportunities are given to help give an improved picture of this market investment for the forecast period of 2020 to 2027.

Key Factors Impacting Market Growth:

o Convergence of data with accuracy and high speedo Rising demand for efficient computingo Increasing opportunities through improved research, computation, and data analysis performanceso High price and data security issues

The main questions answered in the report are:

Reasons to Purchase this Report:

* Estimates 2020-2026 Gene Editing Tools Market development trends with the recent trends and SWOT analysis

* Market dynamics scenario, along with growth opportunities of the market in the years to come

* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects

* Regional and country-level analysis integrating the demand and supply forces that are influencing the growth of the market.

* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years

* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=313215

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

See the rest here:
Gene Editing Tools Market to Witness a Pronounce Growth During 2020-2027 | Top Manufacturers: Thermofisher Scientific, CRISPR Therapeutics, Editas...

CRISPR Technology Industry 2020 Market Research Report A new report added by DeepResearchReports.com to its research database. CRISPR Technology Market is segmented by Regions/Countries. All the key market aspects that influence the CRISPR Technology market currently and will have an impact on it have been assessed and propounded in the CRISPR Technology market research status and development trends reviewed in the new report.

Get Free Sample PDF Copy @ https://www.deepresearchreports.com/contacts/request-sample.php?name=1440039

The economical unrest across the globe due to Covid19 pandemic has affected different industries. Several businesses have gone through revenue hassles. It has impacted many product launches and marketing strategies to an extent that numerous industries and global businesses were compelled to either cease, halt or even shut their operations. Now, when businesses are trying to refurbish their existence across the globe, a ready referral guide in the form of market research report can help in providing a direction with the useful information about the market dynamics.

Next, learn how to build the strategy and business case to implement. Learn about CRISPR Technology market and how it can provide value to your business. In this market, you will find the competitive scenario of the major market players focusing on their sales revenue, customer demands, company profile, import/export scenario, business strategies that will help the emerging market segments in making major business decisions. This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porters Five Forces Analysis.

About the report:

The new tactics of CRISPR Technology market report offers a comprehensive market breakdown on the basis of value, volume, CAGR, and Y-o-Y growth. For business robust expansion, the report suggests new tools and technology development will drive to boom in the near future by 2026. The CRISPR Technology market report provides a comprehensive outline of Invention, Industry Requirement, technology and production analysis considering major factors such as revenue, investments and business growth.

This report for CRISPR Technology Market discovers diverse topics such as regional market scope, product-market various applications, market size according to a specific product, CRISPR Technology sales and revenue by region, manufacturing cost analysis, industrial chain, market effect factors Analysis, and more.

Full Report available @ https://www.deepresearchreports.com/contacts/purchase.php?name=1440039

Table of Contents

Chapter 1 CRISPR Technology Market OverviewChapter 2 Global CRISPR Technology Competition by Players/Suppliers, Type and ApplicationChapter 3 United States CRISPR Technology (Volume, Value and Sales Price)Chapter 4 China CRISPR Technology (Volume, Value and Sales Price)Chapter 5- Europe CRISPR Technology (Volume, Value and Sales Price)Chapter 6 Japan CRISPR Technology (Volume, Value and Sales Price)Chapter 7 Southeast Asia CRISPR Technology (Volume, Value and Sales Price)Chapter 8 India CRISPR Technology (Volume, Value and Sales Price)Chapter 9 Global CRISPR Technology Players/Suppliers Profiles and Sales DataChapter 10 CRISPR Technology Manufacturing Cost AnalysisChapter 11 Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 12 Marketing Strategy Analysis, Distributors/TradersChapter 13 Market Effect Factors AnalysisChapter 14 Global CRISPR Technology Market Forecast (2020-2026)Chapter 15 Research Findings and ConclusionChapter 16 Appendix

Key Questions Answered in this Report:

What is the market size of the CRISPR Technologyindustry?This report covers the historical market size of the industry (2013-2019), and forecasts for 2020 and the next 5 years. Market size includes the total revenues of companies.

What is the outlook for the CRISPR Technologyindustry?This report has over a dozen market forecasts (2020 and the next 5 years) on the industry, including total sales, a number of companies, attractive investment opportunities, operating expenses, and others.

What industry analysis/data exists for the CRISPR Technologyindustry?This report covers key segments and sub-segments, key drivers, restraints, opportunities, and challenges in the market and how they are expected to impact the CRISPR Technologyindustry. Take a look at the table of contents below to see the scope of analysis and data on the industry.

How many companies are in the CRISPR Technologyindustry?This report analyzes the historical and forecasted number of companies, locations in the industry, and breaks them down by company size over time. The report also provides company rank against its competitors with respect to revenue, profit comparison, operational efficiency, cost competitiveness, and market capitalization.

What are the financial metrics for the industry?This report covers many financial metrics for the industry including profitability, Market value- chain, and key trends impacting every node with reference to the companys growth, revenue, return on sales, etc.

What are the most important benchmarks for the CRISPR Technologyindustry?Some of the most important benchmarks for the industry include sales growth, productivity (revenue), operating expense breakdown, span of control, organizational make-up. All of which youll find in this market report.

Inquire More athttps://www.deepresearchreports.com/contacts/inquiry.php?name=1440039

About Us

Deep Research Reports is digital database of syndicated market reports for global and China industries. These reports offer competitive intelligence data for companies in varied market segments and for decision makers at multiple levels in these organizations. We provide 24/7 online and offline support to our customers.

Connect us @ [emailprotected] with subject line 2020 Market Research Report on Global CRISPR Technology Industry and your contact details to purchase this report or get your questions answered. OR Call Us @ +1 888 391 5441.

Follow this link:
Covid-19 Impact on CRISPR Technology Market to Witness Huge Growth by 2026: Future Development and Top Manufacturers Analysis - Verdant News

Fact.MR has recently added a new research report on the global CRISPR and Cas Genes market size to its repository. This report aims to help readers in understanding key technologies as well as product developments in this market during the forecast period of 2020 to 2026. Analysts at Fact.MR highlight that the global CRISPR and Cas Genes market will show growth at a prominent CAGR of 21.2% during the period of analysis.

This report intends to offer an in-depth analysis of various important aspects such as opportunities, drivers, challenges, and restraints of the global CRISPR and Cas Genes market. In addition to this, it provides detailed data on various key players working in this market together with important data on their diverse business strategies to maintain their prominent market position.

The overall share, volume, and other additional important information of important players is also precisely presented in the latest report on the global CRISPR and Cas Genes market. Apart from this, readers get a clear idea about emerging players and the competitive landscape of the market for CRISPR and Cas Genes during the forecast period of 2020 to 2026. This aside, the report covers important data on strengths, weaknesses, and threats of all important vendors in the global CRISPR and Cas Genes market.

The report on the global CRISPR and Cas Genes market offers detailed analysis on various activities that impact on the growth of this market. Thus, the report includes reliable data on partnerships, new product launches, mergers, and acquisitions occurring in the global CRISPR and Cas Genes market during the period of analysis.

To know more about this market trends, drivers, regional analysis request a sample @ https://www.factmr.com/connectus/sample?flag=S&rep_id=4823

Fact.MRs latest report delivers a complete study of the impact of COVID-19 on the CRISPR and Cas Genes market in the present situation. At the same time, it gives readers an idea about the potential effects of the COVID-19 pandemic during the forecast period of 2020 to 2026. The report gives region-wise as well as country-wise data related to the impact of COVID-19 on the growth of the global CRISPR and Cas Genes market. Apart from this, the report talks about diverse strategies executed by industry leaders to deal with this critical situation. This information is intended to assist all key entities while handling critical situations and continuing the work successfully during this pandemic.

The global CRISPR and Cas Genes market study delivers data on the present market situation on regional as well as global levels. In addition to this, it offers forecasts on market development during the assessment period. To offer this top-notch study, the analysts at Fact.MR has utilized diverse industrial as well as digitalization tools. These tools have helped them to present futuristic insights to readers on the global CRISPR and Cas Genes market. In addition to this, the report covers a basic overview of the CRISPR and Cas Genes market and its taxonomy. This data helps in improving the overall reader experience.

Depending on product type, the CRISPR and Cas Genes market report is divided into the following segments:

Based on end-use, the CRISPR and Cas Genes market report is bifurcated into:

Major players profiled in the report on the global CRISPR and Cas Genes market include:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=4823

Key regions covered in the global CRISPR and Cas Genes market report are:

Why Opt For Fact.MR?

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai, United Arab Emirates

MARKET ACCESS DMCC Initiative

Email: sales@factmr.com

Web: https://www.factmr.com/

Press Release: https://www.factmr.com/media-release/1591/global-crispr-and-cas-genes-market

See the article here:
CRISPR and Cas Genes Market to Witness Positive Growth owing to Outbreak of COVID-19, Projects Fact.MR - The Cloud Tribune

Researchers say they have potentially developed a new, more convenient tests for the coronavirus that uses the genetic technology known as CRISPR and could produce results in less than an hour.

The researchers at Massachusetts Institute of Technology and the Broad Institute say the new test, known as STOPCovid, was found to be as accurate as the current molecular test known as aPCR test. They tested 400 patient samples and the new test was found to detect 93% of positive cases.Their findings were published in theNew England Journal of Medicine this week.

"We found that we could essentially match the gold standard," said Jonathan Gootenberg, a McGovern Institute fellow at MIT. "This could be done very rapidly and without expensive instrumentation."

Omar Abudayyeh, another MIT McGovern fellow working on the research, said the test is sensitive and can detect even a low amount of the virus. He said the testing would be most useful as a regular diagnostic tool that would be repeatedly test patients.

"If you're cheap enough and easy enough to run every day, you're going to capture someone when their viral load is high enough that you'll be able to take them out into quarantine before they can spread," Abudayyeh said.

The researchers useda CRISPR-based process to concentrate viral genetic material in a test sample. They said that would eliminate the need for the testing materials that are currently in short supply because of the pandemic, and a commercial lab would not have to process the results.

"Using these technologies will really allow for much more rapid testing down from days to sometimes less than an hour," said MIT McGovern fellow Jonathan Gootenberg. "That would enable a drastic change in how the tracing and handling of the pandemic is done."

They hope to further simplify the test so it can be used by patients at home. Gootenberg said they are working with clinical test developers to have this type of test on the market in a few months.

The researchers worked with other scientists at the University of Washington, Fred Hutchinson Cancer Research Center, Brigham and Women's Hospital, and the Ragon Institute.

See the article here:
MIT, Harvard Researchers Say They're Close To A New Rapid COVID Test - WBUR

An opioid-blocking vaccine could spare many people a lifetime of drug addiction, if and when its developed. COVID-19 exposed Africas inability to mitigate a pandemic; the silver lining is that it focused a spotlight on neglected tropical diseases that plague countries on the continent. Researchers in Israel are using CRISPR gene editing to improve cannabis production, helping ensure a stable supply of medical marijuana for patients all over the world.

Podcast: Play in new window | Download

Subscribe: Apple Podcasts | Android |

Join geneticist Kevin Folta and GLP editor Cameron English on this episode of Science Facts and Fallacies as they break down these latest news stories:

A vaccine for opioid addiction could spare many people a lifetime of drug decadency, and all the tragic side effects that come with it. Three candidate vaccines are currently undergoing clinical trials, but a new study suggests that such a drug may not be effective when its most needed, because the bodys immune system may counteract the vaccines effect.

Drug policy reform advocates have also challenged the ethics of developing an opioid vaccine. Why, they ask, should the federal government invest money in a speculative vaccine when it could fund proven harm-reduction strategies that ultimately reduce drug use? Moreover, could people convicted of drug offenses be required to get an opioid immunization, and who would pay for it?

Plagued by conflict, corrupt governments, poverty and lacking health care infrastructure, Africa was woefully unprepared to combat the coronavirus that rapidly made its way across the globe early in 2020. COVID-19 didnt strike Africa as hard as it did other parts of the world, fortunately enough, but it has highlighted a critical and often overlooked problem in Africa: neglected tropical diseases (NTDs).

As the name implies, these conditions get little attention from the international medical community, because they primarily afflict people in poor countries. A small contingency of infectious disease experts and philanthropies is committed to helping governments tackle the problem, however Africa ultimately has to reform its political institutions and invest in the health care infrastructure that can prevent and treat NTDs.

Researchers are improving all sorts of crops with CRISPR gene editing: everything from wheat, tomatoes and applesto cannabis. A biotech startup in Israel is utilizing the powerful new breeding technique to develop disease-resistant marijuana that can be easily grown from seed (instead of cloned) under greenhouse conditions, the goal being to produce a more stable supply of medical-grade cannabis for patients all over the world.

Subscribe to the Science Facts and Fallacies Podcast on iTunes and Spotify.

Kevin M. Folta is a professor in the Horticultural Sciences Department at the University of Florida. Follow Professor Folta on Twitter @kevinfolta

Cameron J. English is the GLPs managing editor. BIO. Follow him on Twitter @camjenglish

Continued here:
Podcast: CRISPR-edited weed; opioid addiction vaccine; Africa's neglected diseases - Genetic Literacy Project

CRISPR Therapeutics (NASDAQ:CRSP) has had a great run on the share market with its stock up by a significant 19% over the last three months. However, we decided to pay attention to the companys fundamentals which dont appear to give a clear sign about the companys financial health. Specifically, we decided to study CRISPR Therapeutics ROE in this article.

Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Simply put, it is used to assess the profitability of a company in relation to its equity capital.

View our latest analysis for CRISPR Therapeutics

The formula for return on equity is:

Return on Equity = Net Profit (from continuing operations) Shareholders Equity

So, based on the above formula, the ROE for CRISPR Therapeutics is:

2.1% = US$20m US$911m (Based on the trailing twelve months to June 2020).

The return is the income the business earned over the last year. So, this means that for every $1 of its shareholders investments, the company generates a profit of $0.02.

Thus far, we have learned that ROE measures how efficiently a company is generating its profits. Based on how much of its profits the company chooses to reinvest or retain, we are then able to evaluate a companys future ability to generate profits. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that dont necessarily bear these characteristics.

It is quite clear that CRISPR Therapeutics ROE is rather low. Even compared to the average industry ROE of 14%, the companys ROE is quite dismal. Hence, the flat earnings seen by CRISPR Therapeutics over the past five years could probably be the result of it having a lower ROE.

Next, on comparing with the industry net income growth, we found that CRISPR Therapeutics reported growth was lower than the industry growth of 27% in the same period, which is not something we like to see.

The basis for attaching value to a company is, to a great extent, tied to its earnings growth. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. Doing so will help them establish if the stocks future looks promising or ominous. Is CRISPR Therapeutics fairly valued compared to other companies? These 3 valuation measures might help you decide.

CRISPR Therapeutics doesnt pay any dividend, meaning that potentially all of its profits are being reinvested in the business. However, this doesnt explain why the company hasnt seen any growth. So there could be some other explanations in that regard. For instance, the companys business may be deteriorating.

Overall, we have mixed feelings about CRISPR Therapeutics. Even though it appears to be retaining most of its profits, given the low ROE, investors may not be benefitting from all that reinvestment after all. The low earnings growth suggests our theory correct. That being so, the latest analyst forecasts show that the company will continue to see an expansion in its earnings. To know more about the companys future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.

PromotedIf youre looking to trade CRISPR Therapeutics, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. *Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

Original post:
CRISPR Therapeutics AGs (NASDAQ:CRSP) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue? - Simply Wall St

MONDAY 14th September

August transfers from Alibaba show Ant Financial inheriting up to one quarter of the e-commerce giants US portfolio, making it a patent power in its own right. Read more here

The Supreme People's Court hasgranted Chinas first anti-suit injunction in a patent case, ordering Conversant not to enforce aGerman sales ban it won against Huawei in August. Read more here

In extraordinary step, DOJ antitrust head Makan Delrahim calls onthe IEEE to consider changes tolicensing rules which have been bitterly opposed by many top SEP owners. Read more here

TUESDAY 15th September

The Broad Institute has been handed a significant win by the PTAB in its ongoing CRISPR patent battle with UCAL Berkeley. Read more here

Confronting critical challenges, Taiwan's tech companies must find a way to create patent value - IAMspeaks with IP leaders from Foxconn, AU Optronics and others. Read more here

Ireland-based Solas OLED flexes its financial muscle and accuses group of tech giants of infringing patents that originated with Casio. Read more here

WEDNESDAY 16th September

The High Court of Australia could overturn a 112-year-old doctrine of patent exhaustion precedent in a much-awaited ruling that will havebroad commercial implications. Read more here

Speaking at IPBC Connect, the EPO and USPTO leaders say covid-induced changes are here to stay and warn of decreased user engagement caused by the pandemic. Read more here

Efficient infringement is an anathema to Apple, says company CEO Cook in letter to Congressman that also praises the eBay decision and calls for further study of the plague of PAEs. Read more here

THURSDAY 17th September

Ninestar, part of a formidable stable of Chinese companies focused on printing technology, is back in Canons crosshairs after a successful defence against the Japanese giant at the ITC. Read more here

There is growing pressure on US federal agencies and government departments to enforce the patents they own, especially in the life sciences arena. Read more here

The covered business method programme at the PTAB has ended, but efforts to extend it are now being made as influential banking group eyes broader conversation about patents. Read more here

FRIDAY 18th September

Settlements worth hundreds of millions of dollars with the likes of Apple and Samsung have put Korean university KAIST in the licensing big leagues. Read more here

The technological and geographic scope of InterDigitals patent portfolio means new chief licensing officer Eeva Hakoranta has a lot to play with. Read more here

Companies implementing 5G standards must consider the licensing implications of a large chunk of patents that currently lie under the radar. Read more here

SATURDAY 19th September

In this weeks Saturday Opinion, Scott Cleland argues that Googles most effective revenue growth engines have all depended, to an extent at least, on infringing IP owned by leading competitors. Read more here

Book your place at IPBC Connect today

Go here to see the original:
China's first anti-suit injunction; Apple CEO rejects efficient infringement; CRISPR patent battle latest; EPO and USPTO heads' covid warning; CBM...

This article was originally published here

Nat Commun. 2020 Sep 18;11(1):4711. doi: 10.1038/s41467-020-18575-6.

ABSTRACT

The recent outbreak of novel coronavirus (SARS-CoV-2) causing COVID-19 disease spreads rapidly in the world. Rapid and early detection of SARS-CoV-2 facilitates early intervention and prevents the disease spread. Here, we present an All-In-One Dual CRISPR-Cas12a (AIOD-CRISPR) assay for one-pot, ultrasensitive, and visual SARS-CoV-2 detection. By targeting SARS-CoV-2s nucleoprotein gene, two CRISPR RNAs without protospacer adjacent motif (PAM) site limitation are introduced to develop the AIOD-CRISPR assay and detect the nucleic acids with a sensitivity of few copies. We validate the assay by using COVID-19 clinical swab samples and obtain consistent results with RT-PCR assay. Furthermore, a low-cost hand warmer (~$0.3) is used as an incubator of the AIOD-CRISPR assay to detect clinical samples within 20 min, enabling an instrument-free, visual SARS-CoV-2 detection at the point of care. Thus, our method has the significant potential to provide a rapid, sensitive, one-pot point-of-care assay for SARS-CoV-2.

PMID:32948757 | DOI:10.1038/s41467-020-18575-6

Originally posted here:
Ultrasensitive and visual detection of SARS-CoV-2 using all-in-one dual CRISPR-Cas12a assay - DocWire News

ReportsnReports added Latest Emerging Gene Therapies Market Research Report offers crucial data on numerous market situations, for example, ability improvement elements, elements controlling the advancement, market possibilities, and risks to the global market. Also, the report widely facilities round competitive evaluation of Emerging Gene Therapies Market. The competitive evaluation section includes key producers, recent players, providers, market strategies, ability chances, operation panorama, and evaluation of the traits of the Emerging Gene Therapies Market.

Request for FREE Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=1854862

Top Company Profile Analysis in this Report-

AmgenGilead SciencesNovartisSanofiGlaxoSmithKlinePfizer

Emerging Gene Therapies Market Report provides a comprehensive overview of the emerging gene therapy market. The report discusses gene therapy and the technology behind gene editing, outlining the advantages, limitations and current evidence for the platforms under development. The report discusses relevant clinical studies targeting specific therapeutic indications and highlights examples of current challenges within the field, with a focus on therapies that target the eye, liver, and blood.

Additionally, the report provides a background to the CRISPR patent litigation, a key factor within the gene editing company landscape. It provides profiles of six companies developing gene editing platforms, considers the gene therapy interests of the main pharmaceutical companies, and discusses current regulatory trends in the development of gene therapies.

Emerging Gene Therapies Market Report explores how emerging gene editing products will compete with established products, their relative competitive strengths, and upcoming value inflection points within the field.

Scope of this Report- What are the key emerging products within the gene therapy landscape? Which companies have the strongest pipeline of innovative products? How will gene editing disrupt existing gene therapy products? What are the regulatory trends for emerging gene therapies? What are the interests of pharmaceutical companies within the field?

Reasons to buy this Report- Achieve an up-to-date understanding of the area, with a comprehensive reference of key products within the gene therapy landscape, compared across technology-specific relevant characteristics such as editing mechanism and delivery vector. Conduct competitive analysis using indication-specific, side-by-side comparisons of the latest data for key gene therapy products in the strategically relevant areas of eye, blood, and liver. Conduct strategic analysis using an overview of gene therapy specific considerations for evaluating and developing gene therapy products the CRISPR patent space, emerging regulatory trends, innovation leaders and the interests of pharma in gene therapy.

Single User License: US $ 2995

Get FLAT 20% Discount on this Report @ https://www.reportsnreports.com/purchase.aspx?name=1854862

Table of Contents1.1 List of Tables 71.2 List of Figures 82 Introduction 102.1 Gene Therapy Definitions 102.2 Report Coverage the Emerging Gene Therapy Pipeline 112.3 History of Gene Therapy 122.4 Limitations of Gene Transfer 132.5 The Development of Targeted Gene Editing 132.6 Overview of Gene Editing Platforms 132.6.1 Zinc Fingers (1996) 132.6.2 Transcription Activator-Like Effectors (2011) 142.6.3 The CRISPR/Cas System (2013) 152.6.4 Effectors for Targeting Domains 192.6.5 Comparison of Gene Editing Systems 192.6.6 Summary of Gene Editing Systems 192.7 Overview of In Vivo Gene Therapy 212.7.1 Editing is Dependent on Cell Type, Stage, and Repair Pathway 212.7.2 Delivery 212.7.3 Emerging Safety Concerns with Editing Platforms 242.7.4 Editing Products are Reliant on the Target Cells Cycle Stage and DNA Repair Machinery 272.7.5 Advantages of Gene Editing over Gene Transfer 282.7.6 Integration into Safe Harbor Sites 282.7.7 The Increasing Complexity of Gene Therapy 302.7.8 Summary of In Vivo Gene Therapy 313 Gene Therapy Near Term Product Pipeline 333.1 Leber Congenital Amaurosis 333.1.1 Unmet Need 333.1.2 Molecular Genetics 333.1.3 Luxturna (Voretigene neparvovec) 333.1.4 Editas Medicine: EDIT-101 353.1.5 Trial Design 363.1.6 EDIT-101 and Off-Target Effects 373.1.7 The Potential Advantage of EDIT-101 is the Longevity of its Therapeutic Effect 373.1.8 Summary LCA 383.2 Choroideremia 383.3 Hurler Syndrome (MPS I) 393.3.1 Key Clinical Studies 403.3.2 Regenex: RGX-111 403.3.3 Sangamo Therapeutics: SB-318 403.4 Hunter Syndrome (MPS II) 413.4.1 Unmet Need 413.4.2 Sangamo Therapeutics: SB-913 413.4.3 Immusoft Corporation: Cell Therapy 433.5 Sanfilippo Syndrome (MPS III) 433.5.1 Lysogene: LYS-SAF302 433.6 Summary MPS Disorders 443.7 Hemophilia 443.7.1 Hemophilia A 463.7.2 Summary Hemophilia A 503.7.3 Hemophilia B 513.7.4 Summary Hemophilia B 533.8 Hemoglobinopathies 543.8.1 Beta Thalassemia: Unmet Need 543.8.2 Beta Thalassemia: Molecular Genetics 553.8.3 Sickle Cell Disease: Unmet Need 563.8.4 Sickle Cell Disease: Molecular Genetics 563.9 Cellular Therapies for Hemoglobinopathies 573.9.1 Blue Bird Bio: BB-305 (LentiGlobin) 573.9.2 Sangamo: ST-400 603.9.3 CRISPR Therapeutics: CTX-001 613.9.4 Summary: Cellular Therapies for Hemoglobinopathies 623.10 Duchenne Muscular Dystrophy 633.10.1 Unmet Need 633.10.2 Molecular Genetics 633.10.3 ExonDys 51 Sarepta Therapeutics 643.10.4 Solid BioSciences: SGT-001 663.10.5 Exonics Therapeutics: CRISPR Approach 673.10.6 Summary Duchenne Muscular Dystrophy 684 Competitive Landscape 694.1 Regulatory Considerations for Developing Gene Therapy Products 694.1.1 Product Characteristics 694.1.2 Clinical Study Design for Gene Therapy Products 694.1.3 Disease specific guidance 704.1.4 Reimbursement and Payment 714.1.5 Summary Regulatory Considerations 724.2 Intellectual Property CRISPR/Cas 724.2.1 Licensing, Exploitation, and MPEG Pool 744.3 Company Analysis: Gene Editing Companies 754.3.1 Sangamo Therapeutics 754.3.2 CRISPR Therapeutics 794.3.3 Casebia Therapeutics 814.3.4 Editas Medicine 824.3.5 Intellia Therapeutics 844.3.6 Homology Medicines 864.4 Company Analysis: Pharma 874.4.1 Amgen 874.4.2 Gilead Sciences 874.4.3 Novartis 874.4.4 Sanofi 884.4.5 GlaxoSmithKline 884.4.6 Pfizer 885 Appendix 895.1 References 895.2 Report Methodology 98

and more

Here is the original post:
Emerging Gene Therapies Market Report- Technological, Clinical, Regulatory and Competitive Landscape | Amgen, Gilead Sciences - The Daily Chronicle

With an ever-growing CRISPR genome-editing toolbox, scientists are creating crops that can resist diseases and pests, withstand global warming, and offer better nutrition. The emergence of this technology offers a crucial opportunity for renewed public engagement around crop engineering. In order to actualize the potential of CRISPR-edited food, we must work together to create and share strategies for productive dialogue. This article identifies one area of necessary improvement in communication and public engagement.

Describing how CRISPR-edited crops are arguably more natural than GMOs, or how these crops could potentially use fewer chemicals than their GMO predecessors reinforces pervasive societal suspicions of GMOs. If we think that engineered crops will play a key role in addressing environmental and public health issues, then promoting CRISPR-edited crops at the expense of GMOs is short-sighted. Instead, we must use CRISPR as a new avenue for renewing productive discourse with the public. CRISPR offers a way to bring everyone back to the table, reintroducing voices into vital conversations that will impact us all.

The question, Is this safe? captures this tension between distancing CRISPR from GMOs in order to separate a new technology from its polarized relative, while not discarding GMOs and avoiding difficult conversations. Science communicators can use the question Is this safe? as a case study to further identify problematic practices and offer strategies for communication alternatives. Before answering this question, we must better understand the consumers decision-making process.

The processes behind engineering a CRISPR-edited crop and a GMO share many commonalities and, in some instances, lead to nearly identical outcomes .

In the wake of an incoming wave of CRISPR-edited crops, communicators have an opportunity to renew conversations surrounding what is natural, and in doing so, address concerns about naturalness and safety. For science communicators, do we suggest that CRISPR-edited crops are more natural? Do we explain how brands with a natural label dont always align with what consumers think they are buying? Or do we do we zoom out and try to separate natural from safe, so we dont tacitly buy into notions that GMOs are all unsafe?

Read the original post

Read this article:
Promoting CRISPR crops at the expense of GMOs is short-sighted when we need both - Genetic Literacy Project

Myotonic dystrophy type I (DM1) is the most common type of adult-onset muscular dystrophy. DM1 is caused by mutations in the DMPK gene. A normal DMPK gene has 3 to 37 repetitions of the CTG sequence, while in DM1, there are hundreds to thousands of repetitions of this sequence. When a DMPK gene with too many CTG repeats is transcribed, the resulting RNA is too long. This abnormally long RNA is toxic to cells, and those affected experience progressive muscle wasting and weakness.

CRISPR-Cas9 is a technique increasingly used in efforts to correct the genetic defects that cause a variety of diseases. Now a research team from the University of California, San Diego (UCSD), School of Medicine, reports they redirected the technique to modify RNA in a method they call RNA-targeting Cas9 (RCas9), to eliminate the toxic RNA and almost fully reverse symptoms in a mouse model of myotonic dystrophy.

Their findings, The sustained expression of Cas9 targeting toxic RNAs reverses disease phenotypes in mouse models of myotonic dystrophy type 1, was published in Nature Biomedical Engineering and led by Gene Yeo, PhD, professor of cellular and molecular medicine at UCSD School of Medicine.

Myotonic dystrophy is part of a group of inherited disorders called muscular dystrophies. There are two major types of myotonic dystrophy: type 1 and type 2. The muscle weakness associated with type 1 particularly affects muscles farthest from the center of the body, such as those of the lower legs, hands, neck, and face. Muscle weakness in type 2 primarily involves muscles close to the center of the body, such as those of the neck, shoulders, elbows, and hips. The two types of myotonic dystrophy are caused by mutations in different genes.

Many other severe neuromuscular diseases, such as Huntingtons and ALS, are also caused by similar RNA buildup, explained Yeo. There are no cures for these diseases. Yeo led the study with collaborators at Locanabio and the University of Florida.

CRISPR-Cas9 works by directing Cas9 to cut a specific target gene, allowing researchers to inactivate or replace the gene. However, the Cas9 in the RCas9 method is guided to an RNA molecule instead of DNA. In a previous study, Yeo and his team established RCas9 as a means to track RNA in living cells in a programmable manner without genetically encoded tags. In a 2017 study, in lab models and patient-derived cells, the researchers used RCas9 to eliminate 95% of the abnormal RNA linked to myotonic dystrophy type 1 and type 2, one type of ALS and Huntingtons disease.

In the current study, the method goes further, by reversing myotonic dystrophy type 1 in a mouse model of the disease. Toxic RNAs expressed from such repetitive sequences can be eliminated using CRISPR-mediated RNA targeting, yet evidence of its in vivo efficacy and durability is lacking, noted the researchers. Here, using adult and neonatal mouse models of DM1, we show that intramuscular or systemic injections of adeno-associated virus (AAV) vectors encoding nuclease-dead Cas9 and a single-guide RNA targeting CUG repeats results in the expression of the RNA-targeting Cas9 for up to three months, redistribution of the RNA-splicing protein muscleblind-like splicing regulator 1, elimination of foci of toxic RNA, reversal of splicing biomarkers and amelioration of myotonia.

The researchers packaged RCas9 in a non-infectious virus. They then gave the mice a single dose of the therapy or a placebo. RCas9 reduced the abnormal RNA repeats by more than 50%, varying a bit depending on the tissue, and the treated myotonic dystrophy mice became indistinguishable from healthy mice.

To prevent the potential of the RCas9 proteins, developing an immune reaction in the mice, the researchers tried suppressing the mices immune systems briefly during treatment. As a result, they were surprised to see that they successfully prevented immune reaction and clearance. The researchers did not see signs of muscle damage, but found an increase in the activity of genes involved in new muscle formation.

Yeo believes the findings will open a new avenue of understanding and lead the way for treating other genetic diseases. This opens up the floodgates to start testing RNA-targeting CRISPR-Cas9 as a potential approach to treat other human genetic diseasesthere are at least 20 caused by buildup of repetitive RNAs, Yeo added.

Read the original here:
Muscular Dystrophy Condition in Mice Reversed by RNA-Targeting Cas9 - Genetic Engineering & Biotechnology News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today announced the formation of The 221b Foundation, a nonprofit organization committed to addressing the global COVID-19 pandemic by enabling access to intellectual property associated with the companys SHERLOCK CRISPR-based technology. Proceeds from any company or third-party sales of SHERLOCK CRISPR COVID-19 products will support racial and gender diversity in science, technology, engineering, and mathdisciplines collectively known as STEM.

The 221b Foundations initial leadership includes board members Rahul Dhanda, co-founder, president and CEO of Sherlock Biosciences, and Mark Jefferson, assistant dean for community engagement and equity at Harvard Law School.

COVID-19 has undoubtably had a devastating impact on the world. At the same time, there are organizations such as Sherlock that have benefitted by rapidly responding to address the pandemic, which has accelerated our companys innovation and overall plans, said Dhanda. The 221b Foundation is our way of giving back, furthering our commitment to racial and gender diversity especially within the Black Community in STEM, while also sharing our progress with other organizations that can join in the fight against this global pandemic.

The Foundations first partner in this effort is Scratch, the programming language and online community designed for young people ages 8-16. Used in more than 150 countries and available in more than 40 languages, Scratch is committed to helping young people think creatively, reason systematically and work collaboratively. Scratch, which was originally developed at MIT, will dedicate this funding to programs that benefit the Black, Latinx and Native American communities, along with young women and girls.

We are excited to partner with The 221b Foundation to advance our efforts to further equity in computer science education, particularly supporting young people from communities that face systemic inequities and injustice, said Champika Fernando, acting executive director of Scratch. Our commitment to equity and justice throughout all of our work, from the design of our creative coding tools and online community to our outreach programs that support schools and educators, aligns perfectly with The 221b Foundations mission. We look forward to working together to further our shared goal of ensuring representation and equity in STEM throughout the world.

COVID-19 and diversity issues are major crises of our time, both of which are ravaging institutions throughout the world, said Jefferson. I am excited to help The 221b Foundation lead a proactive effort to alleviate the social and healthcare burden through scientific development, educational support and community outreach.

About SHERLOCK

SHERLOCK is a method for single molecule detection of nucleic acid targets and stands for Specific High Sensitivity Enzymatic Reporter unLOCKing. SHERLOCK utilizes CRISPR as a method for smart amplicon detection and can be adapted for use with existing diagnostic instruments, improving time to result due to the technologys large multiplex capacity. When a specific sequence of DNA or RNA is present, the CRISPR enzyme is activated and, much like a pair of scissors, starts cutting nearby genetic material, releasing a fluorescent signal that indicates a positive result.

About The 221b Foundation

The 221b Foundation was founded with the dual mission to assist in the eradication of COVID-19, while supporting racial and gender diversity in STEM. By providing support and intellectual property that enables both non-profit and for-profit entities to develop CRISPR-based diagnostic testing, The 221b Foundation seeks to aid in the fight against the global COVID-19 pandemic while furthering access and diversity in STEM industries. Led by industry experts in the fields of diagnostic testing, STEM and diversity, The 221b Foundation envisions a world where advances in CRISPR technology fuel the innovations that will put an end to the COVID-19 pandemic. For more information, please visit: 221bfoundation.org.

About Sherlock Biosciences

Sherlock Biosciences is dedicated to making molecular diagnostics better, faster and more affordable through Engineering Biology platforms. The company is developing applications of SHERLOCK, a CRISPR-based method to detect and quantify specific genetic sequences, and INSPECTRTM, a Synthetic Biology-based molecular diagnostics platform that is instrument-free. SHERLOCK and INSPECTR can be used in virtually any setting without complex instrumentation, opening up a wide range of potential applications in areas including precision oncology, infection identification, food safety, at-home tests, and disease detection in the field. In May 2020, the company received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Sherlock CRISPR SARS-CoV-2 kit, the first FDA-authorized use of CRISPR technology. For more information visit Sherlock.bio.

Read more from the original source:
Sherlock Biosciences Launches The 221b Foundation to Address the COVID-19 Pandemic and Equity in STEM - Business Wire

Depression is a dark horse.

The disease often goes unnoticed, but affects work performance, social interaction and the ability to take pleasure in everyday life. According to theNational Center for Biotechnology Information, antidepressants only help around 50 percent of those who struggle with depression and anxiety and, even when they are effective, scientists have yet to understand how they work in the brain.

MSU associate professor of physiology A.J. Robison and his lab used new CRISPR-based technology to uncover pathways of depression-like behavior in the mouse brain. Credit: College of Natural Science

But groundbreaking research in the lab of Michigan State University scientistA.J. Robison, associate professor in theDepartment of Physiologyand MSUsNeuroscience Program, is directing some new rays of light onto the molecular, cellular and circuit-level mechanisms underlying depression-like diseases.

Theresultswere recently published inNature Communications.

In this paper, we perform the first ever CRISPR-based gene editing [a genetic engineering technique in molecular biology by which the genomes of living organisms may be modified] in a single circuit between two areas of the mouse brain, explained Robison about the culmination of five years of research funded by the National Institutes of Mental Health. We can reach into the mouse brain and manipulate specific genes in a circuit involved in depression and anxiety-like behaviors a critical advance on the road to genetic medicine for psychiatric diseases.

Scientists estimate there are roughly 80-100 billion neurons connecting regions of the brain. To accomplish the feat of locating and manipulating a single gene in a single circuit required new and sophisticated technology. With the expertise of co-author Rachael Neve, director of theGene Transfer Core at Massachusetts General Hospital, they developed it.

The key advance is that we designed a dual-vector system to manipulate a specific gene in the connections between two brain areas, and that has never been done before, Robison said.

Cross section of a mouse brain. The projections of the cells between the vHPC and NAc, shown here in neon green, are manipulated by the new CRISPR viral vector-based technology developed by Rachael Neve and the Robison Lab. Credit: Andrew Eagle

The neurons that Robison and his team zeroed in on originate in the ventral hippocampus (vHPC), a deep-seated structure that projects to regions in the brain important in stress susceptibility, mood and social avoidance. Neurons rooted in the vHPC reach out with branch-like structures called axons to connect with the nucleus accumbens, or NAc. The completed circuit is regulated by the star of the pioneering paper, the transcription factor known as DFosB.

Using the viral vector technology specifically designed and packaged by Neve, the team split the CRISPR system in half. Half of the system, inert on its own, was an enzyme that can mutate DNA in the vHPC. The other half, a guide RNA, was sent to all cells that project to the NAc and tells the enzyme where to bind and the specific gene to mutate. Only those cells specific to the circuit from the vHPC to the NAc got both halves, triggering the enzyme to bind with and turn off a single gene: FosB.

When the FosB gene was turned off in the neurons, we were able to get a circuit-specific behavioral effect relevant to a disease like depression, said Robison about the landmark discovery. When we put it back, or rescued it within the circuit, the effect was erased.

Claire Manning was a key contributor to the groundbreaking study and is now a postdoctoral researcher at Stanford University. Credit: Ken Moon

One of the most exciting findings from our investigations was the circuit-specific role of the FosB protein in conferring resilience to stress, Eagle said. We also discovered that FosB altered the excitability of hippocampal circuit neurons and may be affecting long-term downstream changes that lead to changes in the activity of this circuit. But removing DFosB permanently altered the expression of a suite of genes, in effect removing the conductor from the orchestra. To that end, the paper goes on to report in-depth experiments on DFosB largely done by the members of theRobison Labincluding co-first authorsClaire Manning, a 2019 neuroscience graduate, now a postdoc at Stanford University; andAndrew Eagle, a former postdoctoral researcher, now an assistant professor in the MSU Department of Physiology.

Andrew Eagle, shown here imaging a mouse brain, played a major role in conducting experiments to further probe the function of DFosB. Credit: Research@MSU.

Based on the findings in the paper, the Robison Lab will continue to develop highly collaborative and cutting-edge techniques, accelerated by MSUs newly completed Interdisciplinary Science and Technology Building. This work is important because it elucidates a potential mechanism, namely FosB, for how stress may contribute to depression, Eagle continued. Future clinical work may find ways to directly manipulate FosB, or more likely one of its gene targets, to provide resilience to stress and decrease the incidence of depression in vulnerable people.

The end of this paper, which shows us measuring the changes of expression in hundreds of genes when we remove DFosB, is only the beginning of years of work for our lab, Robison said. Which genes are important and what are they doing in the brain? This is the challenge of a lifetime for me and my lab.

This article is repurposed content originally featured on the College of Natural Sciences website.

View post:
Illuminating the opaque pathways of depression - MSUToday

The CRISPR and Cas genes market is projected to reflect stupendous growth with a 21.2% CAGR between the years 2020 and 2026. A Fact.MR study has found that that the coronavirus outbreak has generated key lucrative opportunities to participants in the market in the short term. Application of CRISPR technologies diagnosing covid-19 cases, and potential for a cure has is likely to contribute to market growth. Wide ranging field of applications will sustain the high growth for years to come.

CRISPR and Cas gene systems have attracted significant attention among researchers owing to cheaper, faster, and accurate, results in comparison to other existing processes for genome editing. In addition, rising investments in the field by the biotech companies will contribute substantially to the growth of the industry through the forecast period, says the FACT.MR report.

Request a sample of the report to gain more market insights at:https://www.factmr.com/connectus/sample?flag=S&rep_id=4823

CRISPR and Cas Genes Market- Key Takeaways

CRISPR and Cas Genes Market- Driving Factors

CRISPR and Cas Genes Market- Major Restraints

COVID-19 Impact on CRISPR and Cas Genes Market

CRISPR and CAS gene technology developers are likely to benefit from the coronavirus pandemic. Researchers have been studying these technologies as for potential in covid-19 diagnostic applications. In addition, CRISPR is also providing opportunities in terms of a cure through destroying the RNA structure of the virus. The market is expected to continue growing exponentially even in the post-pandemic era owing to applications in plant gene editing and drug development applications for the foreseeable future.

Explore the global CRISPR and Cas Genes market with 88 figures, 24 data tables, along with the table of contents of the report. You can also find detailed segmentation on:https://www.factmr.com/connectus/sample?flag=RM&rep_id=4823

Competitive Landscape

Thermo Fisher Scientific, Addgene, and Integrated DNA Technologies are some of the major players in the CRISPR and Cas gene market.

CRISPR and Cas gene researchers have been investing increasingly in tech innovations and diversification of potential applications for a growing number of end use verticals, supporting long term prospects.

For instance, Thermo Fisher Scientific has collaborated with BioEnergy Science Center to use CRISPR/Cas9 protein delivery for a non-GMO process to edit plant genes. Integrated DNA Technologies has engineered a new high-fidelity Cas9 nuclease through unbiased bacterial screen. Beam Therapeutics is collaborating with Addgene for the commercialization of base editing tools for laboratory use in the United States.

About the Report

This study offers readers a comprehensive market forecast of the CRISPR and Cas gene market. Global, regional and country-level analysis of the top industry trends impacting the CRISPR and Cas gene market is covered in this FACT.MR study. The report offers insights on the CRISPR and Cas gene market on the basis of product (Vector-based Cas and DNA-free Cas), application (genome engineering, disease models, functional genomes, knockdown/activation, and others), and end user (biotechnology & pharmaceutical companies, academic research institutes, and contract research organizations) across five regions (North America, Latin America, Europe, Asia Pacific, and MEA).

Media Release: https://www.factmr.com/media-release/1591/global-crispr-and-cas-genes-market

Visit link:
The Vector-Based Systems to be Highly Lucrative in CRISPR and Cas Genes Market, Fact.MR Study - The Cloud Tribune

Intellia Therapeutics Inc. [NASDAQ: NTLA] gained 8.59% or 1.66 points to close at $20.92 with a heavy trading volume of 1102470 shares. The company report on September 2, 2020 that Intellia Therapeutics to Present at Bairds 2020 Virtual Global Healthcare Conference.

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at Bairds 2020 Virtual Global Healthcare Conference on Wednesday, September 9, 2020 at 10:50 a.m. ET.

A live webcast of Intellias presentation will be accessible through the Events and Presentations page of the Investors & Media section of the companys website at http://www.intelliatx.com. To access the webcast, please log on approximately 15 minutes prior to the start time, to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Intellias website for approximately 14 days following the live event. About Intellia TherapeuticsIntellia Therapeutics is a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or can replace patients diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com and follow us on Twitter @intelliatweets.

It opened the trading session at $19.78, the shares rose to $21.44 and dropped to $19.78, the range by which the price of stock traded the whole day. The daily chart for NTLA points out that the company has recorded 121.56% gains over the past six months. However, it is still -127.89% lower than its most recent low trading price.

If we look at the average trading volume of 784.64K shares, NTLA reached to a volume of 1102470 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NTLA shares is $30.15 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NTLA stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Oppenheimer have made an estimate for Intellia Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on February 28, 2020. The new note on the price target was released on February 14, 2020, representing the official price target for Intellia Therapeutics Inc. stock.

The Average True Range (ATR) for Intellia Therapeutics Inc. is set at 1.32, with the Price to Sales ratio for NTLA stock in the period of the last 12 months amounting to 23.83. The Price to Book ratio for the last quarter was 3.17, with the Price to Cash per share for the same quarter was set at 7.56.

Intellia Therapeutics Inc. [NTLA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.42. With this latest performance, NTLA shares gained by 1.97% in over the last four-week period, additionally plugging by 121.56% over the last 6 months not to mention a rise of 46.77% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NTLA stock in for the last two-week period is set at 54.55, with the RSI for the last a single of trading hit 59.58, and the three-weeks RSI is set at 53.42 for Intellia Therapeutics Inc. [NTLA]. The present Moving Average for the last 50 days of trading for this stock 20.56, while it was recorded at 19.08 for the last single week of trading, and 16.77 for the last 200 days.

Operating Margin for any stock indicates how profitable investing would be, and Intellia Therapeutics Inc. [NTLA] shares currently have an operating margin of -246.78. Intellia Therapeutics Inc.s Net Margin is presently recorded at -230.92.

Return on Total Capital for NTLA is now -37.57, given the latest momentum, and Return on Invested Capital for the company is -35.52. Return on Equity for this stock declined to -36.34, with Return on Assets sitting at -29.21. When it comes to the capital structure of this company, Intellia Therapeutics Inc. [NTLA] has a Total Debt to Total Equity ratio set at 6.81. Additionally, NTLA Total Debt to Total Capital is recorded at 6.37, with Total Debt to Total Assets ending up at 5.50. Long-Term Debt to Equity for the company is recorded at 4.68, with the Long-Term Debt to Total Capital now at 4.38.

Reflecting on the efficiency of the workforce at the company, Intellia Therapeutics Inc. [NTLA] managed to generate an average of -$368,641 per employee. Receivables Turnover for the company is 7.09 with a Total Asset Turnover recorded at a value of 0.13.Intellia Therapeutics Inc.s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.50 and a Current Ratio set at 7.50.

With the latest financial reports released by the company, Intellia Therapeutics Inc. posted -0.49/share EPS, while the average EPS was predicted by analysts to be reported at -0.62/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 21.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NTLA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Intellia Therapeutics Inc. go to 30.00%.

There are presently around $1,130 million, or 83.00% of NTLA stock, in the hands of institutional investors. The top three institutional holders of NTLA stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 11,403,379, which is approximately 11.369% of the companys market cap and around 0.90% of the total institutional ownership; SUMITOMO MITSUI TRUST HOLDINGS, INC., holding 6,195,189 shares of the stock with an approximate value of $129.57 million in NTLA stocks shares; and NIKKO ASSET MANAGEMENT AMERICAS, INC., currently with $129.33 million in NTLA stock with ownership of nearly -12.8% of the companys market capitalization.

Positions in Intellia Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 100 institutional holders increased their position in Intellia Therapeutics Inc. [NASDAQ:NTLA] by around 10,206,052 shares. Additionally, 50 investors decreased positions by around 2,748,793 shares, while 30 investors held positions by with 41,050,254 shares. The mentioned changes placed institutional holdings at 54,005,099 shares, according to the latest SEC report filing. NTLA stock had 42 new institutional investments in for a total of 4,196,261 shares, while 18 institutional investors sold positions of 408,199 shares during the same period.

Link:
Intellia Therapeutics Inc. [NTLA] gain 42.57% so far this year. What now? - The DBT News

Spiderman and CRISPR-Taming Chemist Amit Choudhary both tell us that "with great power comes great responsibility". In Amit's case, he speaks of power and responsibility with CRISPR gene editing technology.

Today, the gene editing tool CRISPR-Cas9 serves as a "genetic 'find and replace' function," that allows one to search and cut a DNA sequence at its precise location.

Yet, this powerful tool must be used with great responsibility, given that a misstep could have irreversible consequences. Amit has pioneered precision tools - small molecule inhibitors, activators, and shredders - to control Cas9 activity. Having successfully fine-tuned CRISPR activity with first generation technologies, Amit is eager to pave the way for everyone to benefit from this gene editing technology safely and responsibly.

Amit's journey with precision control tools for CRISPR-Cas9 demonstrates that responsible use of technology allows us to build solutions that are both effective and finely tuned.

See the original post here:
The Power of CRISPR Cas9 Comes With Great Responsibility - Technology Networks

In November 2018, at a gene-editing summit hosted by scientific societies from the U.S., the U.K., and Hong Kong, a Chinese researcherannouncedthat he had created the worlds first genetically modified babies.He Jiankuifully expected to be celebrated for a scientific breakthrough; hementionedthe Nobel Prize. Instead, he was almost universally condemned.

Key figures associated with theU.S. National AcademiesandU.K. Royal Societyjoined in thecriticismbut did not reject heritable genome editing. Instead, they objected to the Chinese researchers timing. It was too soon, they said. It hadnt been done as they thought it should have been. But according to the researcher now being called a rogue, it was theNational Academies 2017 reportthat had given him the green light for his experiments.

In the aftermath of this headline-grabbing debacle, the scientific societies decided on a do-over. They declared it time to define a rigorous, responsible translational pathway toward clinical use of heritable genome editing. Theyset upa carefully selectedinternational commissionwith themandateto map the scientific details ofhowdesigner-baby technology could be brought to the fertility clinic.

This mandate was flawed from the start. The idea that now is the time to set aside the deeply controversial question ofwhetherheritable genome editing should be done at all so that a small group of experts can settle the nitty-gritty details ofhowit should take place is entirely backward. It flies in the face of the widely shared acknowledgment that scientists alone cannot make this decision; that we must have wide-ranging and inclusive public discussions aimed at buildingbroad societal consensus. It undermines policies in some70 countriesaround the world that prohibit heritable genome editing. And its a slap in the face to the manyscientists,biotech executives,human rights and social justice advocates, and others who support a moratorium or ban on altering the human germline.

The commissions 225-pagereport, released on Sept. 3, does have some strong points. It is more cautious than the previous report, recommending that heritable genome editing should initially be allowed only in the exceedingly rare cases where embryo screening for severe genetic conditions would not be an option. And it paints a vivid picture of the significant technical hurdles facing those eager to pursue heritable human genome editing: shortfalls in the editing tools, in the technologies necessary to test safety and efficacy, even in our understanding of the genetics underlying most heritable diseases.

These findings ought tolay to restthe unfounded assumption that engineering the genomes of human embryos will soon be safe and effective. But even the most cautious considerations of technical safety cant stand-in for the fundamental point that the decision about whether to allow heritable genome editing should be driven by our values, not settled by the science.

The commission claims they are not endorsing heritable genome editing, merely constructing maps of the technological path in case a country should wish to use them. At best, this puts the cart before the horse and sends both horse and cart down a one-way road.

Heritable genome editing cant be separated from its real-world consequences. There are already clear signs that legalizingit would lead to reproductive tourism, jurisdiction shopping, andmission creep. As an example, the U.K.sapprovalof so-called mitochondrial donation for a small number of women with certain mitochondrial DNA diseases wasquickly followedby fertility clinics inUkraine,Spain, and Greeceoffering this high-risk technique, with no evidence of effectiveness, for general and age-related infertility.

A similar trajectory is all too easy to foresee if heritable genome editing is approved, even for limited circumstances. Especially where fertility services are offered on a for-profit basis, its unlikely that any boundaries would hold. We could soon see fertility clinics marketing genetically upgraded embryos, tempting parents-to-be with ads about giving their child the best start in life. From there, a normalized system of market-based eugenics could emerge, exacerbating already existing discrimination, inequality, and conflict.

Amid our multiple ongoing crises, it would be easy to overlook another report on still speculative biotechnology. But this one represents a profoundly consequential step, one that tries to settle in advance the coming decision about whether to engineer genes and traits passed on to future children and generations. Its another attempt to focus discussion on the science, while minimizingthe complex social realities in which scientific and technological developments unfold.

KatieHassonis program director on genetic justice andMarcyDarnovskyis executive director of theCenter for Genetics and Society,a non-profit organization based in Berkeley, California that works to encourage responsible uses and effective governance of human genetic and assisted reproductive technologies.

Excerpt from:
Are we mapping a path to CRISPR babies? | TheHill - The Hill

The genome editor CRISPR, whose invention is at the heart of a fierce patent battle, typically uses an RNA molecule (red) to guide a DNA-cutting enzyme such as Cas9 (orange) to a DNA sequence (blue) targeted for cutting.

By Jon CohenSep. 11, 2020 , 6:40 PM

The long-running patent battle over CRISPR, the genome editor that may bring a Nobel prize and many millions of dollars to whoever is credited with its invention, has taken a new twist that vastly complicates the claims made by a team led by the University of California.

The Patent Trial and Appeal Board (PTAB) ruled 10 September that a group led by the Broad Institute has priority in its already granted patents for uses of the original CRISPR system in eukaryotic cells, which covers potentially lucrative applications in lab-grown human cells or in people directly. But the ruling also gives the University of California group, which the court refers to as CVC because it includes the University of Vienna and scientist Emmanuelle Charpentier, a leg up on the invention of one critical component of the CRISPR tool kit.

This is a major decision by the PTAB, says Jacob Sherkow, a patent attorney at the University of Illinois at Urbana-Champaign who has followed the case closely but is not involved. Theres some language in the opinion from today thats going to cast a long shadow over the ability of the [CVC] patents going forward.

Jennifer Doudna, a biochemist at the University of California at Berkeley, and Charpentier, now with the Max Planck Institute, first published evidence that the bacteria-derived CRISPR system could cut targeted DNA in June 2012, seven months before the Broad team led by Feng Zhang published its own evidence it could be a genome editor. But the CVC team did not show in its initial paper that CRISPR worked inside eukaryotic cells as Zhangs team did in its report, even though the original CVC patent application broadly attempted to cover any use of the technology. The U.S. Patent and Trademark Office issued several CRISPR-related patents to Broad beginning in 2014, sparking a legal a battle in 2016 based on CVC claims of patent interference. That led to a first PTAB trial, which seemed to deliver a mixed verdict, ruling that the eukaryotic CRISPR and other uses of the genome editor were separate inventions, patentable by Broad and CVC respectively. Unsatisfied, CVC took the issue to a federal court, which denied its appeal.

CVC subsequently filed new claims that led PTAB to declare a second interference. The board this time did a more direct comparison of which group had the best evidence for the first demonstration that CRISPR worked in eukaryotic cells. The PTAB ruling did not accept CVC arguments that it crossed this line first, giving the priority edge to the Broad.

This doesnt settle the dispute, however, but instead requires that CVC provide more evidence at a future hearing that it was first. The interference [hearing] is going ahead all the way this time to determine who was the first to invent, says Catherine Coombs, a patent attorney at the U.K legal firm Murgitroyd who has not been involved in the case but handled other CRISPR litigation in Europe. Coombs notes that theres a large gap between the CRISPR patent environment in the United States and Europe, where CVC has won the upper hand in the European Union patent office.

Sherkow anticipates the PTAB will face a tough, complex decision. Its going to need to subpoena Doudna and subpoena Zhang and subpoena a bunch of graduate students and put a bunch of eight-year-old lab notebooks in evidence, says Sherkow.

CRISPR, which typically comprises a DNA-cutting enzyme known as Cas9 and a molecule that guides it to a specific DNA sequence, often is compared to molecular scissors. A key dispute in the patent battle focuses on the guide component. Zhangs first description of CRISPR working in eukaryotic cells used a guide that combined two RNA molecules while CVCs use relied on a single RNA to do the same thing. This single molecule guide RNA now is the standard tool in the field.

A statement from a University of California spokesperson says it is "pleased" with the new ruling, noting that it denied several of the Broads motions. The PTAB "has ruled in our favor in most instances and will continue with the interference proceeding to determine which party was the first to invent CRISPR in eukaryotes, the statement says. [W]e remain confident that the PTAB will ultimately recognize that the Doudna and Charpentier team was first to invent the CRISPR-Cas9 technology in eukaryotic cells.

A statement issued by the Broad calls for something akin to a peace treaty. Although we are prepared to engage in the process before the PTAB and are confident these patents have been properly issued to Broad, we continue to believe it is time for all institutions to move beyond litigation and instead work together to ensure wide, open access to this transformative technology, the statement says. The best thing, for the entire field, is for the parties to reach a resolution and for the field to focus on using CRISPR technology to solve todays real-world problems.

Many observers of the patent battle long have hoped that the Broad and CVC will reach a settlement, but Sherkow thinks its less likely now. Almost every outcome is stacked in Broads favor, he says. If the CVC wins, he says, they will have the patent for the single molecule guide, but the Broad will not lose its eukaryotic patent and, at worst, will have to share it. If CVC loses, theyre toast, they come away empty, says Sherkow. But Ive been wrong about settlement before so theres every expectation that Ill be wrong again.

The PTAB ruling does not specify a date for its next hearing.

View post:
The latest round in the CRISPR patent battle has an apparent victor, but the fight continues - Science Magazine

One of the major challenges facing gene therapy a way to treat disease by replacing a patients defective genes with healthy ones is that it is difficult to safely deliver therapeutic genes to patients without the immune system destroying the gene, and the vehicle carrying it, which can trigger life-threatening widespread inflammation.

Three decades ago researchers thought that gene therapy would be the ultimate treatment for genetically inherited diseases like hemophilia, sickle cell anemia, and genetic diseases of metabolism. But the technology couldnt dodge the immune response.

Since then, researchers have been looking for ways to perfect the technology and control immune responses to the gene or the vehicle. However, many of the strategies tested so far have not been completely successful in overcoming this hurdle.

Drugs that suppress the whole immune system, such as steroids, have been used to dampen the immune response when administering gene therapy. But its difficult to control when and where steroids work in the body, and they create unwanted side effects. My colleague Mo Ebrahimkhani and I wanted to tackle gene therapy with immune-suppressing tools that were easier to control.

I am a medical doctor and synthetic biologist interested in gene therapy because six years ago my father was diagnosed with pancreatic cancer. Pancreatic cancer is one of the deadliest forms of cancer, and the currently available therapeutics usually fail to save patients. As a result, novel treatments such as gene therapy might be the only hope.

[Read: These tech trends defined 2020 so far, according to 5 founders]

Yet, many gene therapies fail because patients either already have pre-existing immunity to the vehicle used to introduce the gene or develop one in the course of therapy. This problem has plagued the field for decades, preventing the widespread application of the technology.

Traditionally scientists use viruses from which dangerous disease-causing genes have been removed as vehicles to transport new genes to specific organs. These genes then produce a product that can compensate for the faulty genes that are inherited genetically. This is how gene therapy works.

Though there have been examples showing that gene therapy was helpful in some genetic diseases, they are still not perfect. Sometimes, a faulty gene is so big that you cant simply fit the healthy replacement in the viruses commonly used in gene therapy.

Another problem is that when the immune system sees a virus, it assumes that it is a disease-causing pathogen and launches an attack to fight it off by producing antibodies and immune response just as happens when people catch any other infectious viruses, like SARS-CoV-2 or the common cold.

Recently, though, with the rise of a gene-editing technology called CRISPR, scientists can do gene therapy differently.

CRISPR can be used in many ways. In its primary role, it acts as a genetic surgeon with a sharp scalpel, enabling scientists to find a genetic defect and correct it within the native genome in desired cells of the organism. It can also repair more than one gene at a time.

Scientists can also use CRISPR to turn off a gene for a short period of time and then turn it back on, or vice versa, without permanently changing the letters of DNA that makes up our genome. This means that researchers like me can leverage CRISPR technology to revolutionize gene therapies in the coming decades.

But to use CRISPR for either of these functions, it still needs to be packaged into a virus to get it into the body. So some challenges, such as preventing the immune response to the gene therapy viruses, still need to be solved for CRISPR-based gene therapies.

Being trained as a synthetic biologist, I teamed up with Ebrahimkhani to use CRISPR to test whether we could shut down a gene that is responsible for the immune response that destroys the gene therapy viruses. Then we investigated whether lowering the activity of the gene, and dulling the immune response, would allow the gene therapy viruses to be more effective.

[Deep knowledge, daily. Sign up for The Conversations newsletter.]

CRISPR can precisely remove even single units of DNA. KEITH CHAMBERS/SCIENCE PHOTO LIBRARY/Getty Images

A gene called Myd88 is a key gene in the immune system and controls the response to bacteria and viruses, including the common gene therapy viruses. We decided to temporarily turn off this gene in the whole body of lab animals.

We injected animals with a collection of the CRISPR molecules that targeted the Myd88 gene and looked to see whether this reduced the number of antibodies that were produced to specifically fight our gene therapy viruses. We were excited to see that the animals that received our treatment using CRISPR produced less antibodies against the virus.

This prompted us to ask what happens if we give the animal a second dose of the gene therapy virus. Usually, the immune response against a gene therapy virus prevents the therapy from being administered multiple times. Thats because after the first dose, the immune system has seen the virus, and on the second dose, antibodies swiftly attack and destroy the virus before it can deliver its cargo.

We saw that animals receiving more than one dose did not show an increase in antibodies against the virus. And, in some cases, the effect of gene therapy improved compared with the animals in which we had not paused the Myd88 gene.

We also did a number of other experiments that proved that tweaking the Myd88 gene can be useful in fighting off other sources of inflammation. That could be useful in diseases like sepsis and even COVID-19.

While we are now beginning to improve this strategy in terms of controlling the activity of the Myd88 gene. Our results, now published in Nature Cell Biology, provide a path forward to program our immune system during gene therapies and other inflammatory responses using the CRISPR technology.

This article is republished from The Conversation by Samira Kiani, Associate Professor of Pathology, University of Pittsburghunder a Creative Commons license. Read the original article.

Read next: Your online branding is key to your business success. Heres your roadmap

See the article here:
How CRISPR is tackling the troubling immune response thats plagued gene therapy until now - TNW

AUSTIN, Texas One of the biggest scientific advances of the last decade is getting better thanks to researchers at The University of Texas at Austin; the University of California, Berkeley; and Korea University. The team has developed a new tool to help scientists choose the best available gene-editing option for a given job, making the technology called CRISPR safer, cheaper and more efficient. The tool is outlined in a paper out today in Nature Biotechnology.

The CRISPR gene-editing technique holds tremendous potential to improve human health, agriculture and the future of people on the planet, but the challenge lies in the delicate nature of gene editing there is almost no room for error.

To edit genes, scientists use dozens of different enzymes from a naturally occurring system called CRISPR. Researchers locate a problematic DNA sequence and use these specialized enzymes to snip it as if using a pair of scissors, allowing genetic material to be added, removed or altered. But these scissors are not perfect. Accuracy and effectiveness vary by the CRISPR enzyme and the project. The new tool guides users, so they can pick the best CRISPR enzyme for their high-stakes gene edit.

We designed a new method that tests the specificity of these different CRISPR enzymes how precise they are robustly against any changes to the DNA sequence that could misdirect them, and in a cleaner way than has ever been done before, said Steve Jones, a UT research scientist who co-wrote the paper with Ilya Finkelstein, an associate professor of molecular biosciences.

Problems can occur when a CRISPR enzyme targets the wrong sections of DNA. Each CRISPR enzyme has strengths and weaknesses in editing different sequences, so the researchers set out to create a tool to help scientists compare the different enzymes and find the best one for a given job.

CRISPR wasnt designed in a lab. It wasnt made by humans for humans. It was made by bacteria to defend against viruses, said John Hawkins, a Ph.D. alumnus who was recently with UTs Oden Institute for Computational Engineering and Sciences. There is incredible potential for its use in medicine, but the first rule of medicine is do no harm. Our work is trying to make CRISPR safer.

The team of researchers developed a library of DNA sequences and measured how accurate each CRISPR enzyme was, how long it took the enzyme to edit the sequences and how precisely they edited the sequence. For some tasks the commonly used enzyme CRISPR-Cas9 worked best; in others, different enzymes performed much better.

Its like a standardized test, Hawkins said. Every student gets the same test, and now you have a benchmark to compare them.

The tool allows scientists to choose the best enzyme for editing on the first try, so the process becomes more efficient and cheaper. Additionally, it gives scientists information about where mistakes are most likely to occur for each enzyme, saving time.

This technique gives us a new way to reduce risk, Jones said. It allows gene edits to be more predictable.

Nicole V. Johnson, Kuang Hu, James R. Rybarski, William H. Press and Ilya J. Finkelstein of The University of Texas at Austin; Cheulhee Jung of Korea University; and Janice S. Chen and Jennifer A. Doudna of University of California, Berkeley, contributed to the research.

The research was funded by a College of Natural Sciences Catalyst Grant, The Welch Foundation and the National Institutes of Health.

See original here:
Matching CRISPR to the Job Improves the Safety, Efficiency of the Gene-Editing Tool - UT News | The University of Texas at Austin

The fight against the novel coronavirus is putting plenty of healthcare ETFs in the spotlight this year, including the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG), but theres much more to the ARKG story.

In fact, ARKG was one of the best-performing healthcare ETFs prior to COVID-19 becoming part of the daily lexicon. Thats a trajectory the actively managed ARK fund can continue when the virus is defeated due to its exposure to disruptive themes, including CRISPR.

Looking ahead, CRISPR-based innovations to accelerate given the technologys ease of use, cost-efficacy, growing body of research surrounding its safety, and AI-powered CRISPR nuclease selection tools. CRISPR could also be utilized to address some of the most prominent healthcare problems, which opens up a significant investment opportunity in monogenic diseases.

In a recent Harvard study, CRISPR gene editing transformed white fat into brown fat that burns energy and can contribute to weight loss, ARK analyst Ali Urman wrote in a recent report. The engineered cells helped mice avoid weight gain and potentially diabetes, despite a high fat diet.

CRISPR can cut DNA/RNA at a single point or in stretches; insert DNA/RNA and create novel gene sequences; activate and silence genes without making permanent changes; regulate protein expression levels epigenetically; record and timestamp biological events; track the movement of specific biological molecules; identify the presence of specific cancer mutations and bacteria; locate molecules without making changes; target and destroy specific viral and bacterial DNA and RNA; interrogate gene function multiplexed, and activate drug release at a specified trigger.

As the aforementioned Harvard study notes, theres a big opportunity for CRISPR as it pertains to fighting to obesity and that could be meaningful for long-term ARKG investors.

This study could have profound implications for CRISPRs total available market. In the United States, more than 34 million people have diabetes and the medical costs and loss of work wages associated with it are valued at $327 billion annually, notes ARKs Urman. If CRISPR were to be effective in increasing insulin sensitivity, CRISPRs total available market would expand significantly, if not exponentially.

ARKG includes companies that merge healthcare with technology and capitalize on the revolution in genomic sequencing. These companies try to better understand how biological information is collected, processed, and applied by reducing guesswork and enhancing precision; restructuring health care, agriculture, pharmaceuticals, and enhancing our quality of life.

For more on disruptive technologies, visit our Disruptive Technology Channel.

The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.

Read the rest here:
CRISPR Benefits Available in This Genomics ETF - ETF Trends

Broadcast Date: October 6, 2020Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Next Spring marks the tenth anniversary of two key moments in the annals of CRISPR. In San Juan, Puerto Rico, Jennifer Doudna, PhD and Emmanuelle Charpentier, PhD discussed a collaboration that would culminate in an immortal paper that repurposed CRISPR-Cas9 into a programmable gene targeting technology. Meanwhile, Feng Zhang heard about CRISPR for the first time, setting him on course to become one of the first investigators to demonstrate genome editing in mammalian cells.

Since the publication of those classic reports in 201213, CRISPR has catalyzed a revolution in genome editing, empowering basic researchers around the world, spawning a multibillion-dollar biotech industry, and showing signs of genuine promise in the clinic. But CRISPR has also been misapplied, notably in the creation of CRISPR babies in 2018, prompting calls for a moratorium on germline editing.

Kevin Davies, PhD, founding executive editor of The CRISPR Journal, has chronicled these events in his new book, Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing. This GEN keynote webinar takes place on the official publication day of the book. Davies will share highlights and insights from his reporting over the past few years and consider some of the exciting new directions that CRISPR will empower in the years ahead.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.

About GEN KEYNOTE webinars:

GEN invites renowned experts to lecture on topics of broad interest to the biotechnology and biomedical community. Look for more GEN KEYNOTE webinars in 2020!

Produced with support from:

Excerpt from:
Heroes and Villains: Reflections on the CRISPR Revolution - Genetic Engineering & Biotechnology News